Jennifer Schneider

CEO at Centauri Therapeutics

Speaker

Jennifer Schneider has been the CEO of Centauri Therapeutics since May 2022 where she was instrumental in closing Centauri’s £24m Series A. Prior to Centauri, Jennifer was Executive Officer for the Global Antibiotic Research & Development Partnership (GARDP), North America. She has nearly twenty years of experience working with companies, universities, and non-governmental organizations in the United States and around the world, providing expertise in antibiotic policy, partnering, and fundraising. Jennifer has raised over $5B in funding and partnerships. Jennifer also participates in US and international discussions surrounding market creation, access, and novel payment models.

Jennifer received her PhD in molecular biology from the University of Notre Dame and her MPH in epidemiology and international health from the University of Michigan.